Browse

alpha-blocker monotherapy in the treatment of nocturia in men with lower urinary tract symptoms: a prospective study of response prediction

DC Field Value Language
dc.contributor.authorPaick, Jae-Seung-
dc.contributor.authorKu, Ja Hyeon-
dc.contributor.authorShin, Jae Wook-
dc.contributor.authorYang, Ji Hyun-
dc.contributor.authorKim, Soo Woong-
dc.date.accessioned2009-10-20T11:40:19Z-
dc.date.available2009-10-20T11:40:19Z-
dc.date.issued2006-
dc.identifier.citationBJU Int 2006; 97: 1017-23en
dc.identifier.issn1464-4096 (Print)-
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16643483-
dc.identifier.urihttps://hdl.handle.net/10371/10565-
dc.description.abstractOBJECTIVE: To determine the efficacy of an alpha-adrenoceptor antagonist, terazosin, in reducing nocturia in men with lower urinary tract symptoms (LUTS), and to identify the factors predicting treatment outcome. PATIENTS AND METHODS: In all, 100 patients were treated with 2 mg of terazosin once daily for the first 7 days, and continued to receive 4 mg of terazosin once daily for the following 3 weeks. The men were assessed at baseline and at the end of treatment using uroflowmetry, the International Prostate Symptom Score (IPSS), and the degree of nocturia estimated from a frequency-volume chart (FVC) and objectively. RESULTS: On the FVC, 27 patients reported that the terazosin treatment reduced their nocturia by more than half, and 14 reported a reduction of 25-49%. On the IPSS, 31 patients reported that the treatment reduced their nocturia by more than half and 27 reported a reduction of 25-49%. On multivariate regression analysis, only the actual number of nightly voids on the FVC was associated with a 2.1-fold chance of an improvement of >25% in objective nocturia (P = 0.016). Using a comparable model, a greater nocturia score on the IPSS was associated with a higher likelihood of improvement in subjective nocturia (odds ratio, 1.653; 95% confidence interval, 1.079-2.533; P = 0.021). CONCLUSION: Treatment with terazosin can reduce patients' episodes of nocturia both subjectively and objectively in some men with LUTS. Our results suggest that both subjective and objective numbers of nocturia episodes are associated with improvements in subjective and objective nocturnal frequencies, respectively.en
dc.language.isoenen
dc.publisherBlackwell Publishingen
dc.subjectnocturiaen
dc.subjectbladderen
dc.subjectDurination disordersen
dc.subjectvoiding diaryen
dc.subjectIPSSen
dc.titlealpha-blocker monotherapy in the treatment of nocturia in men with lower urinary tract symptoms: a prospective study of response predictionen
dc.typeArticleen
dc.contributor.AlternativeAuthor백재승-
dc.contributor.AlternativeAuthor구자현-
dc.contributor.AlternativeAuthor신재욱-
dc.contributor.AlternativeAuthor양지현-
dc.contributor.AlternativeAuthor김수웅-
dc.identifier.doi10.1111/j.1464-410X.2006.06075.x-
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Urology (비뇨기과학전공)Journal Papers (저널논문_비뇨기과학전공)
Files in This Item:
There are no files associated with this item.
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse